Johnson & Johnson Launches Surgical Robot Ottava in Competitive Robotic Surgery Market
Johnson & Johnson has entered the robotic surgery market with its newly FDA-approved surgical robot, Ottava. The device is designed for multiple general surgeries and aims to compete against established players like Intuitive Surgical's da Vinci system. J&J executives believe Ottava’s compact design and integration into existing operating room workflows will help it gain traction over time. The company sees significant growth potential in the surgical robotics market, with U.S. sales projected to rise from $4.4 billion in 2025 to $18.75 billion by 2035. Globally, Precedence Research forecasts a surge to nearly $50 billion during that period. J&J’s deep presence in surgical tools and its MedTech segment position it well for expansion. Despite optimism from management, some analysts remain skeptical about Ottava's market impact due to limited details on pricing or sales expectations. However, the company aims for Ottava to become a material financial contributor within several years.
Topics: FDA approval Intuitive Surgical Johnson & Johnson robotic surgery